You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 119 No. 12, December 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Human Studies, Institutional Review Boards, and the Protection of Human Subjects

Arch Ophthalmol. 2001;119:1849-1850.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE PRINCIPLE that physicians must place the safety and welfare of their patients above all other considerations applies just as surely when physicians are recruiting and studying subjects in clinical investigations as it does when they are caring for the sick. Patient research in one form or another has been conducted for millennia but only in the last several decades and only in certain countries have regulations been promulgated that guide the ethical conduct of human experimentation. At present in the United States, human studies are regulated by the Code of Federal Regulations1 and the revised Declaration of Helsinki.2

The protection of subjects is the special responsibility of boards that evaluate research protocols for the risks that they might pose. These standing institutional review boards or human studies committees also monitor the progress of approved investigations throughout the life of the project. To help ensure that data are obtained in . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Using a Drug Before the Risks and Benefits Are Known From a Phase 3 Clinical Trial: Thoughts on Compassion
Miller
Arch Ophthalmol 2006;124:1029-1031.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.